The National Cancer Institute (NCI) refers to tumor markers, also called biomarkers, as substances that are produced by a tumor or by the host, detectable in biological fluids or tissues and extremely useful to differentiate neoplastic (cancer) from non-neoplastic disease.

XEPTAGEN uses Combinatorial Proteomic®, a unique proprietary platform technology, for the high-throughput identification of novel tumor markers in human tissues undergoing neoplastic events. XEPTAGEN exploits the natural immune response in order to identify these cancer markers coupled to immunoglobulins M. These immune complexes characterize early stage cancer, and therefore are able to provide the earliest form of diagnosis and, in the majority of tumors, they represent the main prognostic factor.